Lasokun

Ranolazine, the active ingredient in Lasokun, is an antianginal agent presented as an oral dosage form for oral use. It is indicated for the treatment of chronic stable angina in adults and works by improving myocardial perfusion. The product is marketed within the European Union and conforms to applicable regulatory standards.

GNH USA supplies Lasokun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, quality assurance and regulatory support for global procurement programmes.

Ranolazine is used in the management of chronic stable angina, an ischemic heart condition.

- Chronic stable angina: reduces the frequency of angina attacks and improves exercise tolerance. - Angina pectoris: alleviates chest pain episodes associated with myocardial ischemia. - Ischemic heart disease: helps balance myocardial oxygen supply and demand, enhancing overall cardiac performance.

Ranolazine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Dizziness - Constipation - Nausea - Headache - Peripheral edema - Palpitations

Serious or Rare Side Effects: - QT interval prolongation - Severe ventricular arrhythmias - Hepatic dysfunction - Hypersensitivity reactions including rash - Angioedema - Pulmonary edema

When prescribing or dispensing Lasokun, several safety considerations should be observed.

- Dose adjustment in renal impairment: reduce dose according to renal function. - Monitor ECG: watch for QT interval prolongation, especially in patients with electrolyte disturbances. - Avoid concomitant strong CYP3A inhibitors: may increase plasma levels and risk of toxicity. - Use caution in patients with hepatic disease: limited data on safety. - Discontinue if severe adverse reactions occur: follow clinical judgment. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Ranolazine can interact with other medicines, requiring attention to the level of risk.

Major Interactions (Avoid): - Strong CYP3A inhibitors (e.g., ketoconazole, clarithromycin): may markedly increase ranolazine exposure. - Strong CYP3A inducers (e.g., rifampin, carbamazepine): can reduce therapeutic effect. - Concurrent QT‑prolonging agents (e.g., sotalol, amiodarone): heighten risk of arrhythmia.

Moderate Interactions (Monitor Closely): - Digoxin: may increase serum digoxin concentrations. - Anticoagulants such as warfarin: monitor INR for potential changes. - Other anti‑anginal drugs (e.g., beta‑blockers, nitrates): assess additive effects on heart function.